Thursday, May 12, 2022 10:33:00 AM
But, during Ken's absence, I was really disappointed with the quality of our corporate communications. This was especially true because Durrant is totally focused on larger issues, such as regulatory authorization/approval, and commencing commercialization. That is how it should be, at this point.
However, shareholder communications is still important, and I'm glad to see consistent messaging, such as Ken provides, even if there are elements of that communication that are redundant, or that I respectfully disagree with.
Three more months will mark the 5th anniversary of my being a HGEN shareholder. So I am likely more tired of waiting than many of you. If any of the various 'accelerated reviews, etc.' we have had over the years meant anything, we could have (and should have) had authorization in March, of 2021.
I don't think Pantginis will be correct regarding his estimate of a 1,455% gain. That's why I started this thread on the topic of sotrovimab. It gives a glimpse into our potential, which could far exceed what Pantginis is projecting.
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM